Insider · CIK 0001166440
David Platt
Files at BIXT (BIOXYTRAN, INC). First filing -, latest -.
In brief
David Platt files SEC Form 4 as CEO, director and 10% owner at BIXT (BIOXYTRAN, INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David Platt has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 24, 2024 | BIXT BIOXYTRAN, INC | JOther preferredindirect: through NDPD Pharma | -14,085,410 | $0.29 | $4.0M | 0 | Nov 18, 2025 |
| Oct 24, 2024 | BIXT BIOXYTRAN, INC | JOther preferred | +11,433,448 | $0.55 | $6.2M | 20,038,903 | Nov 18, 2025 |
| Oct 25, 2024 | BIXT BIOXYTRAN, INC | JOther Preferredindirect: through NDPD Pharma | -14,085,410 | $0.29 | $4.0M | 0 | Oct 28, 2024 |
| Oct 25, 2024 | BIXT BIOXYTRAN, INC | JOther Preferred | +11,190,077 | $0.55 | $6.1M | 19,795,532 | Oct 28, 2024 |
| Mar 27, 2024 | BIXT BIOXYTRAN, INC | AGrant or award commonindirect: by NDPD Pharma, Inc. | +439,595 | $0.10 | $46k | 20,133,018 | Mar 27, 2024 |
| Jan 16, 2024 | BIXT BIOXYTRAN, INC | AGrant or award common stockindirect: by NDPD Pharma, Inc. | +3,599,289 | $0.14 | $486k | 19,693,423 | Jan 16, 2024 |
Questions about David Platt
Answered from the filings on this page, as of the latest one.
Is David Platt buying or selling?
David Platt has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David Platt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Platt has 0.
Where does David Platt file Form 4?
David Platt has filed Form 4 at BIXT (BIOXYTRAN, INC) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.